Efpeglenatide is primarily used in the management of type 2 diabetes. It functions as a GLP-1 receptor agonist, helping to regulate blood sugar levels by enhancing insulin secretion and suppressing glucagon release. This medication is particularly effective in improving glycemic control when used in conjunction with diet and exercise. Additionally, it has shown potential benefits in weight management, as it can promote a feeling of fullness and reduce appetite. Efpeglenatide is administered via subcutaneous injection, typically on a weekly basis, making it a convenient option for patients seeking long-term diabetes management. Its use has also been associated with a lower risk of hypoglycemia compared to some other diabetes treatments, contributing to its safety profile.